To deepen the strategic synergy and cultural integration between Tianshu Pharmaceutical and Vcare PharmaTech Headquarters, and enhance the comprehensive capabilities of management personnel, over 20 middle and senior managers from Tianshu Pharmaceutical traveled to Nanjing on August 9-10 to conduct a two-day special training and exchange activity with more than 110 personnel from Vcare PharmaTech's R&D Headquarters.
This activity covered three key sessions: a skill enhancement training program, a R&D-production-marketing synergy seminar, and a laboratory visit. It precisely focused on strengthening management capabilities, addressing business pain points, promoting R&D-production synergy and in-depth integration, injecting new impetus into Tianshu Pharmaceutical's high-quality development. During the activity, some managers and key post backbones of Tianshu Pharmaceutical participated synchronously via remote video.
Targeting the management challenges and needs in the new stage of enterprise development, this training program carefully designed a more targeted curriculum system, covering enterprise lean management and improvement, Integrated Product Development (IPD), etc. Through various forms such as expert lectures, case studies, practical drills, and group discussions, it stimulated in-depth thinking and interactive communication among participants.
In future work, all trainees will transform the gains from this training into a strong driving force for their work, deeply integrate advanced management concepts, practical execution tools, and innovative methods into daily management, fully implement the concepts of lean production and IPD-based R&D-production-marketing synergy, and contribute more to the high-quality development of Vcare PharmaTech and Tianshu Pharmaceutical.
During the training, all middle and senior managers of Tianshu Pharmaceutical held two special R&D-production-marketing synergy seminars with leaders and department heads of Vcare PharmaTech. Heads of Tianshu Pharmaceutical's General Manager's Office, Production, Quality, Sales, Finance and other departments faced current pain points and blockages directly, and systematically reported the existing problems in their work and the issues requiring support from the headquarters.
Leaders of Vcare PharmaTech responded on-site: "The headquarters will establish a regular technical dialogue mechanism between the R&D and production ends to accelerate the in-depth integration of R&D and production cultures of both parties. We will form a 'problem list' and tracking mechanism for the issues raised at this seminar, arrange dedicated personnel from each department to follow up, and fully empower Tianshu Pharmaceutical in technical research, resource allocation, and talent support."
After the training and seminars, led by Chairman Zhou Xipeng, the middle and senior managers of Tianshu Pharmaceutical visited the laboratories of various technical platforms of Vcare PharmaTech in depth, personally experiencing Vcare PharmaTech's R&D culture of "Focus, Rigor, and Excellence". They observed on-site technical platforms such as synthesis, instrumental analysis, formulation R&D, polymorphism research, preparative separation, continuous flow, and bioenzymology, and conducted in-depth exchanges with the R&D team on issues such as process scale-up, effectively promoting mutual understanding and cultural collision between the two parties in R&D concepts and production thinking.
This exchange activity achieved the three goals of management empowerment, problem-solving, and strategic alignment. Chairman Zhou Xipeng emphasized in his summary: "Through this series of activities including training programs and seminars, our understanding of lean production and IPD integrated R&D has been significantly enhanced, and the pain points and blockages in the integration of R&D-production-marketing have been effectively addressed. The focused and rigorous R&D and innovation culture of Vcare PharmaTech Headquarters and Tianshu Pharmaceutical's lean production culture are the driving forces for us to continuously forge core competitiveness. We will strive to promote the in-depth integration of advantageous cultures, continuously unblock the integrated value chain of 'R&D-Production-Marketing', and create more value for customers."
